Pediatric fibroblastic/myofibroblastic lesions are a relatively common group of tumors with varying morphologies, for which the molecular mechanisms are becoming increasingly well characterized. Congenital infantile fibrosarcoma (CIFS), perhaps the most well studied of these lesions is characterized by a recurrent ETV6-NTRK3 gene fusion. However, a notable subset of locally aggressive congenital/infantile soft tissue lesions with similar morphologic features to CIFS, have not to-date, shown evidence of any canonical molecular aberration. We describe 6 patients with mesenchymal tumors composed of infiltrative fibroblastic/myofibroblastic tumor cells and showing a morphologic spectrum of features much analogous to that previously described in CIFS but without ETV6 fusion transcripts. These tumors lacked a uniform immunoprofile, but showed variable expression of CD34, S100, smooth muscle actin, and CD30. All patients first developed a mass in infancy ( 2 months of age). Using next-generation DNA sequencing, TMP3-NTRK1 fusions were identified in 4 cases, an LMNA-NTRK1 fusion in one case, and a variant EML4-NTRK3 fusion in one case. Similar to infantile fibrosarcoma, these tumors were locally aggressive (with local recurrences if incompletely excised) and rarely metastasized (lung metastases in one patient). Proper identification of these tumors including investigation for NTRK family gene rearrangements is essential for diagnostic accuracy, as well as for clinical management decisions. Given the morbidity associated with radical resection of large soft tissue tumors, children with unresectable, recurrent, and/or metastatic disease may benefit from treatment with NTRK targeted therapies.
Introduction
Infantile fibroblastic and myofibroblastic tumors, comprising a spectrum of diagnostic entities, are the second most common group of soft tissue neoplasms to occur in the first year of life. [1] [2] [3] [4] In infancy, the majority of fibroblastic/myofibroblastic neoplasms are either benign or intermediate/low-grade malignant, with congenital infantile fibrosarcoma (CIFS) as the primary malignant concern.
1,2,4,5 CIFS is a locally aggressive tumor, occurring almost exclusively in children under the age of 2 years. 1, 6, 7 Morphologic overlap can exist between CIFS and a spectrum of benign or malignant infantile lesions, including myofibroma/myofibromatosis, lipofibromatosis and fibrous hamartoma of infancy, primitive myxoid mesenchymal tumor of infancy (PMMTI), and dermatofibrosarcoma protuberans (DFSP). 6, [8] [9] [10] [11] [12] [13] Molecular tests are useful in confirming the diagnosis of CIFS, particularly in morphologically challenging cases, as CIFS is characterized cytogenetically by nonrandom gains of chromosome 8, 11, 17 , and 20, and more specifically by an ETV6-NTRK3 gene fusion. 6, [14] [15] [16] [17] However, a subset of tumors occurring in infants may resemble CIFS, including shared non-random chromosomal gains, but lack the canonical ETV6-NTRK3 fusion.
Herein, we describe a series of 6 infants who presented with locally aggressive soft tissue neoplasms demonstrating a spectrum of morphologic features reminiscent of those seen in CIFS but lacking ETV6-NTRK3 fusions. In contrast, these tumors were found to have variant NTRK1 or NTRK3 gene fusions.
Materials and Methods
Since 2011, 6 patients (5 prospectively, 1 retrospectively) were identified at 2 institutions (SCH, n ¼ 5 and UCSF, n ¼ 1), with low-grade spindle cell tumors lacking evidence of ETV6 fusion by fluorescence in situ hybridization (FISH). Hematoxylin and eosin (H&E) and immunohistochemical (IHC) stains performed at the time of diagnosis were reviewed, and these results were supplemented with additional IHC stains (see below). Clinical and follow-up data were obtained from the electronic medical record. The study was approved by the institutional review board.
Immunohistochemistry
Immunohistochemistry was performed on 4-mm paraffinembedded whole tissue sections using standard techniques. Detection and staining for all cases used a fully automated DAB antigen retrieval system (Benchmark ULTRA; Ventana Medical Systems, Tuscan, AZ). The following antibodies were utilized: rabbit monoclonal anti-NTRK1 (EP1058Y, 1:250 dilution; Epitomics), mouse monoclonal anti-CD34 antibody (MU-236-4C, 1:30 dilution; BioGenex), rabbit polyclonal anti-S100 (Z0311, 1:800 dilution; Dako), mouse monoclonal antineurofilament (M0726, 1:400 dilution; Dako), mouse monoclonal anti-smooth muscle actin (SMA) antibody (M085101, 1:200; Dako), mouse monoclonal antimuscle specific actin (HHF-35) antibody (M635, 1:400 dilution; Dako), mouse monoclonal anti-myogenin antibody (M-3559, 1:800; Dako), mouse monoclonal antidesmin antibody (M0760, 1:800 dilution; Dako), mouse monoclonal anti-EMA antibody (247M-96, 1:100; Cell Marque), mouse monoclonal anti-CK7 antibody (M7018, 1:800 dilution; Dako), mouse monoclonal anti-CD99 (O13) antibody (SIG620-1000, 1:200 dilution; Covance), and mouse monoclonal anti-CD30 antibody (13M-96, 1:50 dilution; Cell Marque). Appropriate positive and negative controls were used for each antibody.
Electron Microscopy
For the initial biopsy material from case 2, multiple 1-2 mm fragments of tumor tissue were fixed in glutaraldehyde and embedded in resin for possible future examination. This material was retrieved to complete the ultrastructural examination.
Cytogenetics/Karyotype
Giemsa-trypsin-wright(GTW)-banded metaphase cells from 2 unstimulated cultures of tumor specimens (collagenase-disaggregated; harvested between days 6 and 10) were analyzed.
Fluorescence In Situ Hybridization
Interphase FISH was performed on touch imprint slides or unstained FFPE tissue sections using dual-color, 
DNA Sequencing With Fusion Detection
UW-OncoPlex is a validated, clinical molecular diagnostic assay that can detect all classes of mutations as previously described. 18, 19 Briefly, H&E-stained slides were used to direct tumor tissue microdissection from formalin-fixed, paraffin-embedded blocks. A minimum of 200 ng of genomic DNA was extracted, fragmented (Covaris, Woburn, MA), and used to prepare sequencing libraries (KAPA Hyper Prep, Kapa Biosystems, Wilmington, MA). Following custom hybrid capture (SureSelect; Agilent Technologies, Santa Clara, CA), targeted next-generation sequencing (NGS) (NetSeq; Illumina, San Diego, CA) was performed to yield >500Â average coverage in 262 clinically relevant genes. A custom bioinformatics pipeline was used as previously described. 19 Structural rearrangements, including gene fusions, were identified using PINDEL version 0.2.5, 20 CREST version 1.0.1, 21 and BreakDancer version 1.4.4.
22

Results
Clinical Characteristics
Patient 1 presented at 2 months of age with an enlarging 4 cm mass in the forearm ( Table 1 ). The tumor was diagnosed as CIFS, although it lacked evidence of ETV6 rearrangement by FISH. The patient was treated with 9 weeks of neoadjuvant chemotherapy including vincristine and dactinomycin. 23 He then underwent a gross total surgical resection, with positive margins, but received no further chemotherapy. The tumor recurred 7 months later and a second gross total resection was performed, again with positive margins, after which he was managed with active surveillance. During this process, NGS sequencing was performed to inform future treatment options; however, he has received no further chemotherapy and remains disease free 27 months following his initial diagnosis.
Patient 2 presented at birth with a 6.3-cm mass involving the lower leg. The tumor was low grade, with a differential diagnosis of myofibromatosis versus CIFS. Again, the tumor lacked evidence of ETV6 rearrangement. The patient was treated with neoadjuvant vinblastine and methotrexate for 1 year 24 with no significant change in the size of the mass. Ten months after completion of chemotherapy, a new enhancing lesion adjacent to the original tumor developed. The mass was surgically resected with positive margins, but he received no additional chemotherapy at that time. Twenty months later, the tumor again increased in size. Given the extensive involvement of the neurovascular bundle, a subtotal resection was performed. He was treated with sulindac for approximately 6 months with mild symptomatic improvement but no change on imaging. NGS testing was performed to inform possible treatment options, and subsequently he enrolled on a clinical trial investigating a pan-NTRK inhibitor.
Patient 3 presented at 2 months of age with a superficial mass on the lower back. A punch biopsy of skin showed a low-grade spindle cell lesion involving the dermis and subcutaneous tissues, which was subsequently widely resected. On resection, the lesion was diagnosed as a myxoid DFSP with negative margins. She has had no recurrence of disease and is now more than 6 years after definitive resection.
Patient 4 presented 2 weeks of age with a rapidly enlarging right axillary mass. An MRI at 8 months showed a 5-cm heterogeneous lesion thought to be compatible with a hemangioma. The patient underwent surgical resection at age 9 months with negative margins. The pathology specimen showed an unclassified spindle and round cell sarcoma, with the leading differential diagnosis including CIFS and PMMTI; however, the tumor lacked an ETV6 rearrangement. No systemic therapy was given. The patient has had regular surveillance with no evidence of recurrence or metastases at 21 months post resection.
Patient 5 presented at birth with a right foot mass, and foot asymmetry had been detected on prenatal ultrasounds. The mass was biopsied at 9 days of age and showed a low-grade spindle cell lesion with a differential diagnosis of fibromatosis versus CIFS, but which lacked evidence of an ETV6 rearrangement. At 3 years of age, he became symptomatic and a needle biopsy demonstrated tumor progression to a high-grade spindle cell sarcoma. He had no metastatic disease and was treated with 2 cycles of ifosfamide/doxorubicin followed by 2 cycles of ifosfamide alone. Subsequent imaging revealed local tumor progression and a right foot amputation was performed. Follow-up imaging 1 year later demonstrated multiple metastatic lung nodules, confirmed by biopsy. The original pathology was reviewed, and given the morphologic similarity to prior cases, NGS testing was performed. He is enrolled on a clinical trial investigating a pan-NTRK inhibitor.
Patient 6 developed a left heel mass at 2 months of age which enlarged rapidly. At 4 months of age, the lesion was biopsied. The tumor was diagnosed as a low-grade spindle cell lesion and, given the histologic similarity to the prior cases, tissue was sent for further molecular testing. Given the tumor proximity to the calcaneus and Achilles tendon, gross total resection was considered too morbid. Instead, he was enrolled on a clinical trial of a pan-NTRK inhibitor. 
Microscopic Features and Immunohistochemistry
All 6 patients showed a low-grade spindle cell composed of a highly infiltrative, cellular, ovoid to spindled neoplasm. The 5 deep tumors showed extensive infiltration of both fat and skeletal muscle (Figure 1(A) , (B), (D) to (F)). The neoplastic cells were occasionally arranged in sheets or broad fascicles, with a myxoid to collagenous stroma (Figure 2 (B) to (C)). Areas resembling primitive mesenchymal cells with small ovoid cells with scant amphophilic cytoplasm were present in all 6 patients ( Figure 1 ). The one superficial neoplasm (patient 3) involved subcutaneous adipose tissue with ''honeycomb/pearls on a string'' fat trapping (Figure 1 (C)) with weak CD34 staining, raising the possibility of a myxoid DFSP. In all cases, individual cells were ovoid to spindled with vesicular nuclei and indistinct nucleoli. Mitoses on the original biopsies were low, ranging <1 to 3 per 10 high power fields; however, the recurrences had increased mitotic activity ranging from 6 to 15 per 10 high power fields (Table 1) . No necrosis was seen.
There was moderate variation in other histologic features seen in these cases (Figure 2 ). Three cases showed myoid/myofibroblastic differentiation with abundant eosinophilic cytoplasm (Figure 2(A) ). In 3 cases (all TPM3-NTRK1 fusions), these regions surrounded hypercellular islands of smaller cells having indistinct, amphophilic cytoplasm and a variably myxoid background creating a superficial resemblance to fibrous hamartoma of infancy (Figure 2(B) to (C) ). Three cases showed prominent hemangiopericytomatous vasculature (Figure 2(B) and (C)), and one case showed focally prominent nuclear palisading (Figure 2(D) ).
In 2 cases (patients 2 and 5), the tumor morphology changed on recurrence, with increased pleomorphism and cytologic atypia similar to that which has been described in recurrent/residual infantile fibrosarcoma. In these specimens, both post chemotherapy, the cells became dyshesive and epithelioid with hyperchromatic nuclei showing scattered nuclear pseudoinclusions but inconspicuous nucleoli (Figure 3 ). There were abundant admixed inflammatory cells including lymphocytes and eosinophils, with resemblance to inflammatory myofibroblastic tumor (IMT) on these recurrence specimens (Figure 3) . The IHC profile was non-specific but analogous to that seen in CIFS. CD34 and CD30 were the most commonly expressed antibodies; variable expression of SMA and S100 was also observed ( Figure 4 , Table 2 ). No cases had strong diffuse staining for S100; the most prominent S100 expression observed was focal and patchy ( Figure 4(B) ). All cases showed staining for NTRK1 ( Figure 5 , Table 2 ). The 4 patients with TPM3-NTRK1 fusions showed strong, diffuse cytoplasmic staining, while the pattern associated with other fusions was more variable (Table 2) . Upon local recurrence, patient 1 showed gain of S100 expression and patient 2 demonstrated new CD34 expression (Table 2) ; the meaning of these findings is unclear on this limited sample. NTRK1 expression remained unchanged in recurrence and metastasis.
G-Banded Chromosome Results
Patient 1: 52,XY,þ2,þ2,þ8,þ12,þ17,þ20 [3] /46,XY [17] . An abnormal hyperdiploid clone was present. Seventeen cells exhibited a normal male karyotype. The remaining 3 cells displayed tetrasomy for chromosome 2 and trisomies for chromosomes 8, 12, 17, and 20.
Patient 2: The karyotype from the original biopsy was normal male, 46,XY [20] . The karyotype from the first tumor recurrence was 46,XY [19] . Nineteen cells exhibited a normal male karyotype, 46,XY. A single cell had 47 chromosomes, with the extra chromosome approximately the size of a C-group chromosome, could not be definitively identified due to poor morphology, but based on size and interphase FISH results, it was thought to represent a cell with trisomy 8 (see interphase FISH result below).
Patient 3: 46,XX [56] . This study was a limited sample due to poor growth in culture. Five of the 6 cells analyzed demonstrated a normal female karyotype. One of the 6 cells showed a non-clonal deletion of the long arm of one chromosome 9 at band q12, a finding seen in peripheral blood cultures attributable to an artifact of cell culture. One of the 6 cells also demonstrated a non-clonal deletion of the long arm of chromosome 1, with a breakpoint at band q11.
Patient 5: The karyotype from the initial biopsy was normal male, 46,XY [20] . 
Fluorescence In Situ Hybridization
BL2x2)[100]
). Given the superficial location and original diagnosis of DFSP, FISH for ETV6 was not performed in patient 3.
DNA Sequencing With Fusion Detection
Tumors from patients 1, 2, 5, and 6 demonstrated TPM3-NTRK1 fusions by clinical NGS. The translocations joined the tropomyosin-3 gene with NTRK1 exon 9, which is upstream of the kinase domain, and are predicted to maintain the reading frame ( Figure 6 ). Tumor from patient 3 was positive for a LMNA-NTRK1 translocation that joins the lamin-A gene with NTRK1 exon 11, which is also upstream of the kinase domain, and the reading frame is predicted to be maintained ( Figure 6) . Tumor from patient 4 demonstrated an EML4-NTRK3 fusion that joins the EML4 gene with NTRK3 exon 14, which is upstream of the kinase domain, and the reading frame is predicted to be maintained ( Figure 6 ).
Electron Microscopy
Ultrastructural examination, on the initial biopsy from patient 2, showed cells with mitochondria admixed with abundant smooth and rough endoplasmic reticulum and fine, filamentous extracellular matrix material. The filamentous material lacked organization into identifiable actin or collagen fibrils. There were scattered cell processes and occasional cells showed microvesicles, but no neurosecretory granules were identified. The cells lacked cell junctions and basal lamina. Overall, the ultrastructural features were those of undifferentiated mesenchymal cells; no neural or other differentiation was identified.
Discussion
CIFS is a tumor of intermediate malignant potential characterized by presentation below the age of 2 to 5 years, often an initial period of rapid growth, local recurrence following incomplete resection (17% to 43%) and uncommon metastatic spread (1% to 13%). CIFS harbors a canonical t(12;15)(p13;q25) translocation encoding an ETV6-NTRK3 gene fusion, which is detected in approximately 85% of tumors. 23 We report a series of 6 NTRK-associated mesenchymal tumors, all originally presenting in infants less than 6 months of age, but lacking ETV6 rearrangements. These tumors appear to share many clinicopathologic features with CIFS, and recognition of variant NTRK fusions in these otherwise undifferentiated mesenchymal tumors is important for accurate diagnosis and treatment.
NTRK1 (1q21-q22) is one member of a family of genes, along with NTRK2 (9q21-22) and NTRK3 (15q25), which encode for a series of tropomyosin- Table 2 . Ancillary Studies. receptor kinases (TRKs). [25] [26] [27] These TRK proteins play an integral role in central and peripheral nervous system development by means of cell cycle regulation, cellular proliferation, and cell differentiation primarily through activation of the RAS-RAF-MAPK pathway. However, TRK receptors are also expressed on a host of other nonneuronal tissues. 25, 26, 28 Gene fusions involving NTRK family members have been implicated as driver mutations in a variety of tumors, and tumors with NTRK gene fusions are heavily weighted towards pediatrics/young adults. 25, [29] [30] [31] [32] [33] Over the past 3 decades, NTRK gene fusions have been identified in pediatric gliomas (NTRK1, NTRK2, NTRK3), papillary thyroid carcinoma (NTRK1), spitzoid neoplasms (NTRK1), and infantile fibrosarcoma (NTRK3) among others.
14,25,33-37 NTRK1 fusions have only recently been described in soft tissue neoplasms/ sarcomas. [38] [39] [40] [41] [42] The first case of a spindle cell sarcoma with an LMNA-NTRK1 gene fusion arising in an infant was reported by Wong et al. 38 This patient presented at 1 month of age, and ultimately developed lung metastases which responded to targeted therapy (Crizotinib). Subsequently, Haller et al. 39 described a series of 2 adult and 2 pediatric (less than 2 years of age) soft tissue sarcomas with a myopericytic/hemangiopericytic pattern and NTRK1 rearrangements, including LMNA-NTRK1 and TPM3-NTRK1. Doebele et al. 40 reported a similar tumor in an adult patient with lung metastases and confirmed an LMNA-NTRK1 fusion. Variant NTRK3 fusions have also rarely been reported in CIFS, including one report of a novel EML4-NTRK3 fusion in a patient who developed lung metastases. 41 More recently, genomic profiling studies have found a variety of NTRK fusions in adolescent and pediatric tumors; however, the morphology and clinical course of these tumor are not described. 42 Although we also encountered one patient with metastatic disease, the number of metastatic tumors with NTRK1 rearrangements may be over-represented in these early case reports given that NGS platforms are often offered only to patients who have failed prior therapy.
Finally, Agaram et al. 43 recently described a series of locally aggressive soft tissue tumors occurring in patients ranging 4 to 38 years in age, which demonstrated predominantly fusions of LMNA-NTRK1. The morphology of these tumors was described as lipofibromatosis-like, with extensive infiltration into fat, and they showed consistent strong, diffuse S100 expression. 43 Given the reported strong, diffuse expression of S100 and the role of the NTRK family of genes in neurodevelopment, the classification ''lipofibromatosis-like neural tumor'' was suggested. 43 It is not yet clear whether lipofibromatosis-like neural tumor represents a unique tumor type, with more diffuse S100 expression and perhaps with preferential occurrence in an older patient population than seen in our series of infantile NTRK tumors, or whether these tumors characterized by a superficial location and are simply more amenable to resection and therefore better outcomes.
Although all the cases of NTRK-associated soft tissue tumors reported in the literature share many histologic features, it has been challenging to draw definitive morphologic correlates from limited case series and case reports. Our series of 6 patients, all presenting at 2 months of age or under, demonstrate tumors with significant overlap in the morphologic spectrum of features seen in CIFS. The morphologic intratumoral heterogeneity in our series lead to initial differential diagnoses of CIFS, PPMTI, myofibromatosis, and DFSP, which is further complicated by the significant histologic overlap which may be present between these diagnostic entities. For instance, an overlap between ETV6-NTRK3 positive CIFS and infantile myofibromatosis has previously been described and it was hypothesized that CIFS has the potential to differentiate along a myopericytic lineage. 8 Additionally, focal Hemangiopericytoma(HPC)-like growth has been described in CIFS. 7, 8 DFSP, characterized by recurrent COL1A1-PDGFB rearrangements, may show a variety of histologic subtypes, including myxoid and/or myoid differentiation. 13, 44, 45 The presence of CD34 positivity in an infiltrative, superficial spindle cell lesion should prompt consideration of this diagnosis, but the NTRK-associated tumors had a more fascicular and less storiform architecture overall with weak or patchy CD34 expression. DFSP is also distinctly uncommon under the age of 2 years. The presence of primitive ovoid cells in a markedly myxoid matrix may also raise the consideration, particularly in an infant, of PMMTI, characterized by internal tandem duplication repeats in BCOR or YWHEA gene rearrangements. 12, 46 However, morphologically, the NTRK-associated tumors typically show more fascicular Figure 6 . NTRK gene fusion partners. A, schematic of a generalized TRK protein, as well as TRKA and TRKC oncogenic protein fusions. Shown are the TPM3-TRKA fusion (patients 1, 2, 5, 6), the LMNA-TRKA fusion (patient 3), and the EML4-TRKC fusion (patient 4). The ETV6-TRKC fusion, classic to CIFS is shown for reference, although it was not present in this series. B, Genomic structure of the NTRK1 and NTRK3 genes with exons indicated by boxes. Each arrow represents a patient case with an NTRK1 or NTRK3 fusion.
growth and lack the chicken-wire type vascular pattern typical of PMMTI.
The most characteristic morphologic feature of these NTRK-associated mesenchymal tumors is a highly infiltrative, cellular proliferation of primitive ovoid cells, with a pale basophilic myxoid to eosinophilic collagenized stroma, much analogous to that seen in CIFS. Additionally, similar to CIFS, these variant NTRK-associated tumors show no consistent immunophenotype with variable expression of several proteins including CD34, S100, CD30, and SMA (Table 2) , and by cytogenetics, there are non-random chromosomal gains. 6, 7, 11, [15] [16] [17] Overall, histologic identification of these NTRK-associated mesenchymal tumors may be challenging and may lead to misdiagnosis as a variety of other entities or lack of a definitive diagnosis. However, awareness that NTRK rearrangements occur in a subset of soft tissue tumors is of increasing importance for clinical treatment and management. Like both ''lipofibromatosis-like neural tumor'' and CIFS, this spectrum of NTRK-associated mesenchymal tumors seems to be predominantly locally aggressive due to their highly infiltrative growth, but they may not require additional therapy if completely excised. In patients for whom a complete resection would be too morbid (ie, requiring amputation for negative margins), pan-TRK inhibitors are now available as therapeutic options. Early studies have shown responses to treatment with Ertrectinib (RXDX-101) in metastatic colorectal carcinomas and LMNA-NTRK1 soft tissue tumors, 38, 47, 48 as well as with Afatinib (LOXO-101) in CIFS and in the single adult case of LMNA-NTRK1 soft tissue sarcoma. 39, 49 Given the tremendous morbidity associated with resection of large deep soft tissue tumors in young infants particularly, wide resection is often not favored as a first-line therapeutic approach, and the addition of these targeted therapies may improve outcome.
Together, our experience suggests that NTRK-associated mesenchymal tumors in infants show morphologic overlap and clinical behavior analogous to that seen in CIFS, but with variant NTRK fusions. We suggest referring to these neoplasms as NTRK-associated mesenchymal tumors to emphasize the common molecular features and potential role of targeted therapies for patients with locally aggressive disease.
